S&P Futures
4,066.25 +61.50 (+1.54%) Dow Futures
32,549.00 +390.00 (+1.21%) Nasdaq Futures
12,478.75 +234.00 (+1.91%) Russell 2000 Futures
1,815.70 +33.30 (+1.87%) Crude Oil
115.38 +1.18 (+1.03%) Gold
1,833.90 +19.90 (+1.10%)
Merck & Co., Inc. (MRK.BA)
Chart Events
Performance Outlook
| Previous Close | 3,849.50 |
| Open | 3,838.00 |
| Bid | 3,900.00 x 0 |
| Ask | 3,923.00 x 0 |
| Day's Range | 3,838.00 - 3,974.00 |
| 52 Week Range | 2,390.50 - 3,999.00 |
| Volume | |
| Avg. Volume | 1,608 |
| Market Cap | 27.436T |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 5,623.05 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 61.74 (1.66%) |
| Ex-Dividend Date | Mar 14, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRK.BA
Related Research
- Reuters
Generic drugmakers to sell Pfizer's Paxlovid for $25 or less in low-income countries
Several generic drugmakers that will produce versions of Pfizer's COVID-19 antiviral treatment Paxlovid have agreed to sell the medicine in low- and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on Thursday. CHAI said it could not disclose the names of the manufacturers who have agreed to the price ceiling, because they are still in the early stage of product development and have not received regulatory approval.
- Reuters
RPT-New class of cancer drugs down, not out, after Roche trial setback - analysts
The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone. The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.
- Reuters
New class of cancer drugs down, not out, after Roche trial setback - analysts
The fresh blow to Roche's hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on Wednesday, but the latest setback is not the end of the road for these oncology treatments, analysts say. Roche said an interim analysis of an ongoing clinical trial showed that its experimental drug, tiragolumab, failed to meaningfully slow disease progression in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with its approved PD-L1 immunotherapy Tecentriq, versus Tecentriq alone. The study will continue to evaluate whether the combination helps patients live longer, the gold standard for cancer treatments.
